The tumor lysis syndrome (TLS) commonly occurs in the lymphoproliferative disorder, either spontaneously or in response to therapy. TLS is uncommon in multiple myeloma. However, with the use of bortezomib in the treatment of multiple myeloma, cases of TLS have been reported. We report here threepatients who presented with TLS after the administration of bortezomib. Two of them presented mild symptoms and recovered with hydration only. However, death of the other patient was associated with TLS. We should monitor patients who had high tumor burden, especially in early phase of bortezomib therapy and appropriate prophylaxis for high risk patient is also needed.
INTRODUCTION
The tumor lysis syndrome (TLS) commonly occurs in lymphoproliferative disorders, either spontaneously or in response to therapy. But TLS is uncommon in multiple myeloma. However, after use of bortezomib in the treatment of multiple myeloma, cases of TLS have been reported. Here we describe three patients who presented with TLS after treatment of bortezomib in two university hospitals (case 1 in Soonchunhyang University Hospital, Seoul, and case 2/case 3 is in Soonchunhyang University Hospital, Bucheon, Korea).
CASE REPORTS

Case 1
A 61-year-old man presented with a week history of back pain.
He was diagnosed of Immunoglobulin G κ multiple myeloma. M protein was 6.0 g/dL in serum protein electrophoresis. Bone marrow examination showed 56.1% plasma cell infiltration. β2-microglobulin was 4.7 mg/L and serum lactate dehydrogenase (LDH) was 150 U/L (normal: 106-211 U/L).
The patient was treated with bortezomib (1. Because there was no other cause of increased LDH, we started intravenous hydration with sodium bicarbonate for alkalinization to him. A week later LDH was back to normal.
Case 2
A 61-year-old woman had a diagnosis of immunoglobulin G λ multiple myeloma. Bone marrow examination showed 67% plasma cell infiltration. After three cycles of thalidomide and dexamethasone, she presented with severe asthenia that she could not receive chemotherapy anymore. But after one month later, she presented with both leg weakness due to aggravated back pain, she received local radiotherapy for lumbar spine and again one month later, percutaneous vertebroplasty.
http://jsms.sch.ac.kr Bortezomib is a reversible inhibitor of the 26S proteasome approved for the treatment of multiple myeloma. Bortezomib is a highly active drug in multiple myeloma treatments and its effect was rapid [3] . The most serious side effect of bortezomib is peripheral peripheral neuropathy (range, 37% to 44%) [4] . Although concern about TLS is low because of its low incidence, TLS reported more commonly as increased use of bortezomib containing regimen including first line treatment for patients with high tumor burden. One phase 1/2 study reported 1 episode of TLS among 10 patients who treated bortezomib and melphalan combination in patients with the relapsed multiple myeloma [5] . Other phase II multicenter studies reported 8 episodes of TLS among 497 patients in bortezomib therapy, with or without dexamethasone [1] . Clinically, because of almost treatment of multiple myeloma taken in the outpatient clinic and LDH is not routinely tested, the incidence of TLS related with bortezomib could be underestimated.
In one series, patients with rapidly proliferative disease and a high tumor burden appear to be at greatest risk for TLS [6] . One case report reported TLS with bortezomib on the patient had a high tumor burden and carried an unfavorable karyotype [7] .
Hence, we could presume the amount of M protein that reflect tumor burden is related with risk of TLS, but has not been adequately evaluated. In our case, case 2 and 3 has TLS although low M protein.
Other previous case reports also revealed tumor lysis occurring within the first cycle of treatment of bortezomib due to rapidity of bortezomib action [8] [9] [10] . In our cases, 2 of them experienced TLS after fourth dose of first cycle, but, the other one, it occurred after first dose of second cycle. Therefore we need more studies about risk factor and time of development.
Bortezomib associated TLS is usually mild form and almost of cases treated just symptomatic management including appropriate hydration, allopurinol administration. But some cases were required intermittent dialysis due to renal deterioration. Also, it is potentially life-threatening complication.
As the bortezomib widely used in multiple myeloma, TLS occurs more frequently. It seems the patient with TLS in Korea is also increasing by expanding of health assurance coverage as the firstline treatment for patients with multiple myeloma. We should monitor patient who had high tumor burden, especially in early phase of bortezomib therapy and appropriate prophylaxis for high risk patient is also need. And more studies about risk factors are needed.
